BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference

  SeaStar Medical Holding Corporation announces that management will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 at 9:30 a.m. Eastern time.

  April 11, 2024

   · 

  1 min read
• Business

  Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer

  Orna Therapeutics today announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer.

  April 11, 2024

   · 

  3 min read
• Business

  Incyte to Report First Quarter Financial Results - April 11, 2024

  Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2024.

  April 11, 2024

   · 

  1 min read
• Business

  Citius Pharmaceuticals Announces Addition of City of Hope to UMN’s Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

  Citius Pharmaceuticals, Inc. today announced that the University of Minnesota Masonic Cancer Center intends to expand their ongoing investigator-initiated Phase 1 trial of LYMPHIR™ (denileukin diftitox) in combination with FDA-approved CAR-T products for the treatment of B-cell lymphomas.

  April 11, 2024

   · 

  7 min read
• Drug Development

  Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

  Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.

  April 11, 2024

   · 

  8 min read
• Biotech Beach

  Palisade Bio to Participate in the Virtual Investor Lunch Break Event

  Palisade Bio, Inc. announced that it will present at the Virtual Investor Lunch Break Featuring Palisade Bio event on Tuesday, April 16, 2024 at 12:00 PM ET.

  April 11, 2024

   · 

  1 min read